全文获取类型
收费全文 | 13570篇 |
免费 | 767篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 117篇 |
儿科学 | 442篇 |
妇产科学 | 211篇 |
基础医学 | 1679篇 |
口腔科学 | 407篇 |
临床医学 | 1399篇 |
内科学 | 2725篇 |
皮肤病学 | 165篇 |
神经病学 | 1294篇 |
特种医学 | 364篇 |
外科学 | 2138篇 |
综合类 | 105篇 |
一般理论 | 9篇 |
预防医学 | 900篇 |
眼科学 | 312篇 |
药学 | 1080篇 |
中国医学 | 19篇 |
肿瘤学 | 1000篇 |
出版年
2023年 | 107篇 |
2022年 | 133篇 |
2021年 | 261篇 |
2020年 | 229篇 |
2019年 | 323篇 |
2018年 | 318篇 |
2017年 | 295篇 |
2016年 | 321篇 |
2015年 | 321篇 |
2014年 | 455篇 |
2013年 | 708篇 |
2012年 | 927篇 |
2011年 | 922篇 |
2010年 | 495篇 |
2009年 | 489篇 |
2008年 | 829篇 |
2007年 | 871篇 |
2006年 | 812篇 |
2005年 | 746篇 |
2004年 | 734篇 |
2003年 | 690篇 |
2002年 | 630篇 |
2001年 | 149篇 |
2000年 | 126篇 |
1999年 | 161篇 |
1998年 | 181篇 |
1997年 | 161篇 |
1996年 | 123篇 |
1995年 | 115篇 |
1994年 | 114篇 |
1993年 | 87篇 |
1992年 | 92篇 |
1991年 | 104篇 |
1990年 | 99篇 |
1989年 | 94篇 |
1988年 | 78篇 |
1987年 | 74篇 |
1986年 | 87篇 |
1985年 | 107篇 |
1984年 | 83篇 |
1983年 | 63篇 |
1982年 | 96篇 |
1981年 | 57篇 |
1980年 | 52篇 |
1979年 | 54篇 |
1978年 | 40篇 |
1977年 | 33篇 |
1976年 | 36篇 |
1974年 | 26篇 |
1973年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Anders Larsson 《Food and Agricultural Immunology》1999,11(1):43-49
Chicken antibodies have several advantages over mammalian antibodies due to the phylogenetical differences between birds and mammals, resulting in an increased sensitivity and a decreased background in many immunological assays. So far, there has been a very limited use of avian antibodies. This is probably partly due to tradition but also because there are very few optimized methods for the labelling of chicken antibodies. We report upon the suitable conditions for peroxidase-labelling of chicken antibodies with a modified periodate method. 相似文献
992.
993.
Susanne Lerche Liselotte Soendergaard Joergen Rungby Niels Moeller† Jens Juul Holst‡ Ole E. Schmitz Birgitte Brock 《Clinical endocrinology》2009,71(4):500-506
Objective It is uncertain whether the ability to avoid hypoglycaemia during fasting is preserved, and the risk of reactive hypoglycaemia after an oral glucose stimulus following a prolonged fasting period is increased at augmented glucagon-like peptide-1 (GLP-1) levels.
Design A randomized, double-blind placebo-controlled cross-over study in eight healthy men to assess the safety, in terms of hypoglycaemia, of a continuously infused pharmacological dose of native GLP-1 during long-term fasting. After an overnight fast the fasting period continued for 48 h and was followed by a 3-h oral glucose tolerance test (OGTT). GLP-1(7-36 amide) or placebo was continuously infused subcutaneously and titrated to a dose of 4·8 pmol/kg per min.
Results Two subjects in the GLP-1 group and one subject in the placebo group were withdrawn due to protocol specified plasma glucose (PG) ≤ 2·8 m m and neuroglycopaenic symptoms.
The infusion of GLP-1 resulted in pharmacological levels of intact GLP-1. During the fasting period PG, insulin and C-peptide levels declined and glucagon, GH and free fatty acid (FFA) levels increased with no differences between GLP-1 and placebo. During OGTT circulating levels of insulin and C-peptide were higher with GLP-1 infusion. However, PG was similar during GLP-1 vs. placebo infusions. GLP-1 infusion increased norepinephrine and cortisol levels during OGTT.
Conclusion The counter-regulatory response during 48 h of subcutaneous GLP-1 infusion was preserved despite long-term fasting with no apparent increased risk of hypoglycaemic episodes. No reactive hypoglycaemia was observed when the fast was followed by an OGTT. Thus use of long-acting GLP-1 analogues may not increase the risk of hypoglycaemia. 相似文献
Design A randomized, double-blind placebo-controlled cross-over study in eight healthy men to assess the safety, in terms of hypoglycaemia, of a continuously infused pharmacological dose of native GLP-1 during long-term fasting. After an overnight fast the fasting period continued for 48 h and was followed by a 3-h oral glucose tolerance test (OGTT). GLP-1(7-36 amide) or placebo was continuously infused subcutaneously and titrated to a dose of 4·8 pmol/kg per min.
Results Two subjects in the GLP-1 group and one subject in the placebo group were withdrawn due to protocol specified plasma glucose (PG) ≤ 2·8 m m and neuroglycopaenic symptoms.
The infusion of GLP-1 resulted in pharmacological levels of intact GLP-1. During the fasting period PG, insulin and C-peptide levels declined and glucagon, GH and free fatty acid (FFA) levels increased with no differences between GLP-1 and placebo. During OGTT circulating levels of insulin and C-peptide were higher with GLP-1 infusion. However, PG was similar during GLP-1 vs. placebo infusions. GLP-1 infusion increased norepinephrine and cortisol levels during OGTT.
Conclusion The counter-regulatory response during 48 h of subcutaneous GLP-1 infusion was preserved despite long-term fasting with no apparent increased risk of hypoglycaemic episodes. No reactive hypoglycaemia was observed when the fast was followed by an OGTT. Thus use of long-acting GLP-1 analogues may not increase the risk of hypoglycaemia. 相似文献
994.
995.
996.
BackgroundWe report the outcomes of a prospective consecutive series of 267 total ankle replacements (TARs) using a new mobile bearing Rebalance® prosthesis.MethodsBetween April 2011 and December 2018, 267 consecutive Rebalance® prostheses were implanted in 255 patients at 3 different centers. Estimated survival curves with 95% confidence intervals were produced with the Kaplan–Meier method. 110 ankles were followed for at least 5 years and clinical and radiological outcomes were assessed in 92 of these ankles.ResultsTwenty-one ankles were revised at a mean of 34 (7–60) months. The estimated survival was 90% (95% CI 86–95) at 5 years and 88.3% (95% CI 83.–94 at 6 years. The ankles followed for at least 5 years demonstrated a median Likert score of 1 (1–4). Radiolucent zones were detected in 14% and osteolytic cysts in 3%.ConclusionThe survival rate of the Rebalance prosthesis conforms with other reports of similar designs. The satisfaction rate was high. Radiological zones and osteolytic cysts were found at a lower rate than usually reported for mobile bearing TARs. These results favour further use of this implant. 相似文献
997.
998.
999.
1000.